首页> 外文期刊>Science Advances >Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells
【24h】

Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells

机译:抑制组蛋白甲基转移酶DOT1L使ERα基因沉默并阻断抗雌激素耐药性乳腺癌细胞的增殖

获取原文
           

摘要

Breast cancer (BC) resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor α (ERα) signaling, and ways to block ERα pathway in these tumors are sought after. We identified the H3K79 methyltransferase DOT1L as a novel cofactor of ERα in BC cell chromatin, where the two proteins colocalize to regulate estrogen target gene transcription. DOT1L blockade reduces proliferation of hormone-responsive BC cells in vivo and in vitro, consequent to cell cycle arrest and apoptotic cell death, with widespread effects on ER-dependent gene transcription, including ERα and FOXA1 gene silencing. Antiestrogen-resistant BC cells respond to DOT1L inhibition also in mouse xenografts, with reduction in ERα levels, H3K79 methylation, and tumor growth. These results indicate that DOT1L is an exploitable epigenetic target for treatment of endocrine therapy–resistant ERα-positive BCs.
机译:乳腺癌(BC)对内分泌治疗的抗药性是由组成性活性或异常雌激素受体α(ERα)信号产生的,并寻求在这些肿瘤中阻断ERα途径的方法。我们确定H3K79甲基转移酶DOT1L是BC细胞染色质中ERα的新辅助因子,其中这两种蛋白共定位以调节雌激素靶基因转录。 DOT1L阻断剂可降低体内和体外激素反应性BC细胞的增殖,这是细胞周期停滞和凋亡性细胞死亡的结果,对ER依赖的基因转录(包括ERα和FOXA1基因沉默)具有广泛的影响。抗雌激素的BC细胞在小鼠异种移植物中也对DOT1L抑制产生反应,导致ERα水平降低,H3K79甲基化和肿瘤生长。这些结果表明,DOT1L是可用于治疗内分泌治疗耐药的ERα阳性BC的表观遗传学靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号